Project description
Innovative device for treatment of chronic obstructive pulmonary disease
Chronic obstructive pulmonary disease (COPD) represents a group of debilitating respiratory conditions, such as emphysema and chronic bronchitis, characterised by lung airflow limitations, cough and reduced lung functional capacity. COPD could be associated with cigarette smoking and exposure to air pollutants, killing millions of people worldwide each year. The Israel company Respinova has developed a device for COPD treatment via opening the small airways, which usually collapse in COPD patients, creating difficulty to breathe. The device prototype passed the clinical trial, improving the lung’s functional capabilities in patients with COPD. The EU-funded PulseHaler project will conduct a feasibility study that involves market analysis, clinical and technical risk assessment, and stakeholders identifications.
Objective
Chronic obstructive pulmonary disease (COPD) is a group of progressive, debilitating respiratory conditions, including emphysema and chronic bronchitis, characterized by difficulty breathing, lung airflow limitations, cough, and markedly reduced functional capacity. COPD often is associated with a history of cigarette smoking or exposure to pollutants. It kills approximately 270,000 people in the EU annually, equivalent to the size of the entire city of Venice. It affects 4% and 10% of adults in Europe (Halbert et al., 2003). World-wide 5-10% are affected and 3 million die each year (source: WHO). In the developing countries, COPD has been growing dramatically due to increased air pollution, smoking and massive use of biomass fuels for cooking.
Respinova has developed a novel non-invasive technology and medical device named the PulseHaler™, that aims to treat the core of the COPD pathophysiology – small airway collapse.
The technology was successfully validated in two clinical studies. In the first study, PulseHaler was evaluated for its ability to open small airways. Clinical results demonstrated unprecedented improvements in the 6 minute walk test (6MW), spirometry lung functions tests and in the feeling of dyspnoea. All of these effects were above and beyond the effect of standard pharmaceutical care.
In the second study, PulseHaler™ was successfully used as a new means for improved delivery of inhaled drugs to the terminal bronchioles and the alveolar zone in COPD patients. It resulted in three-fold enhancement of penetration index, a measure of efficiency of drug delivery. By improving the drug delivery, PulseHaler technology can enhance efficacy & safety of drug delivery. It can reduce the amount of drug required, ensure less drug goes to non-lung areas (mouth, stomach etc.), and reduce time required to deliver the drugs.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences clinical medicine pneumology
- medical and health sciences basic medicine physiology pathophysiology
- natural sciences earth and related environmental sciences environmental sciences pollution
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.3.1.4. - Active ageing and self-management of health
See all projects funded under this programme -
H2020-EU.2.1.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT)
See all projects funded under this programme -
H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument
See all projects funded under this programme -
H2020-EU.3.1.6. - Health care provision and integrated care
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
SME-1 - SME instrument phase 1
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-SMEInst-2016-2017
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
4672408 Herzliya Pituach
Israel
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.